The Market Research Future (MRFR) report has suggested an overall CAGR growth of around 3.9 percent for the global Neurosyphilis market during the forecast period 2017-2023. A per the report, the Neurosyphilis market’s revenue will reach around USD 957.4 million by 2023. Neurosyphilis is an infection of the brain or the spinal cord that is caused by the bacteria Treponema pallidum.
The disease occurs in the individuals who have had untreated syphilis for a long period of time. If the person suffers from syphilis for the first time, then he or she may suffer from neurosyphilis after 10-20 years if the treatment is not done for curing syphilis. The main symptoms of neurosyphilis include blindness, abnormal walk, dementia, depression, confusion, headache, irritability, poor concentration, incontinence, numbness in feet, toes or legs, stiff neck, tremors, seizures, visual disturbances as well as weakness. Also, there is possibility that no symptoms will occur in the case of neurosyphilis.
Among all types of neurosyphilis, the asymptomatic neurosyphilis is the most common one. The MRFR report suggested that the upsurge in funding for research, new product development and the clinical trials are expected to boost the global neurosyphilis market growth during the forecast period. Nowadays, the government, as well as private companies, are investing a large sum of money to cure neurosyphilis effectively. They are now adopting technologically advanced or high-tech diagnostic medical devices which can play a major role in the upsurge of market growth of Neurosyphilis.
The global neurosyphilis market growth is driven many other factors like increasing awareness, growing demand from emerging markets, government’s support for improvement of public healthcare, and enhancement of good healthcare practices. The four major regions of neurosyphilis market are America, Europe, Asia Pacific and the Middle East and Africa. Among them, America, constituting both North America and Latin America, is the highest revenue generating region in the global neurosyphilis market. According to MRFR report, advanced diagnostic and treatment facilities, increased funding for research, clinical trials as well as new drugs development along with quick adaptation of new therapies, have made the U.S. the leader of the global Neurosyphilis market.